Lastly, our siRNA study (Figs 2 and S3) and animal heterozygosity (Figs 4 and S6), where DNAJB9 mRNA were only partially downregulated, suggesting that DNAJB9 might be a limiting factor in CFTR ERAD pathway and that targeting DNAJB9 using specific inhibitor may turn out to be an important strategy in correcting Cystic Fibrosis effectively. This evidence concerns the gene DNAJB9 and cystic fibrosis.